Maison Solutions Inc. (MSS)
Consumer Defensive · Grocery Stores · NASDAQ · US
$1.63+4.49%Close
BUYCRISIS · day 4
$1.63+4.49%
Key stats
Short interest · FINRA settlement 2026-09-15
- Market cap
- $682,538
- Beta
- 4.15
- P/E (TTM)
- -0.06
- Short % float
- 60.33%
- Days to cover
- 1.0
- SI change
- -52.0%
- 1W
- -1.81%
- 1M
- +10.14%
- vs SPY 1W
- -3.01%
- vs SPY 1M
- +9.67%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Maison Solutions Inc. Receives Additional Nasdaq Notification Regarding Delayed Filing of Quarterly Report on Form 10-Q
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Maison Solutions Eliminates All Outstanding Convertible Notes, Removing Legacy Financing Overhang
Maison Solutions Inc. Receives Nasdaq Notification Regarding Delayed Filing of Annual Report on Form 10-K
ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"
Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal
Maison Solutions Inc. Receives 2026 Global Recognition Award in Innovation Category
Maison Solutions Issues Letter to Shareholders on Operational Reset, Recent Transaction Value and the Company's Path Forward
Maison Solutions Regains Compliance with Nasdaq Annual Meeting Requirement
Maison Solutions Signs Definitive Agreement to Establish Majority-Controlled AI Technology Platform
Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth
Maison Solutions Announces Reverse Stock Split
Water Tower Research Publishes Initiation of Coverage Report on Maison Solutions, Inc., "Putting the "AI" in Maison: A Leaner Store Base Meets a Smarter Grocery Platform"
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
Why Maison Solutions Shares Are Trading Higher By Over 62%; Here Are 20 Stocks Moving Premarket
